Liminatus Pharma, Inc. (LIMN) Latest Filing Signal
Cross-checked across multiple AI analysts and grounded in the latest SEC filing.
powered by: earningsVibe.ai
Question:
What is the latest filing signal for Liminatus Pharma, Inc.?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest
10-K, Liminatus Pharma, Inc.'s filing signal
continuing negative.
earningsVibe SuperAnalyst™ Verdict:
CONTINUING NEGATIVE
Signal Performance — Stock Price Since Filing
30-Day Change
Pending
from filing date
60-Day Change
Pending
from filing date
Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT
PERPLEXITY
Continuing Negative
GEMINI
Continuing Negative
CLAUDE
Continuing Negative
CHATGPT
Continuing Negative
Unlock the Full Filing Analysis
See full earningsSig™ and risksSig™ analysis across 5,000+ companies
Get Started Free →No credit card required
Question:
What does Liminatus Pharma, Inc. actually do?
Answer:
Liminatus Pharma, Inc. is a pre-clinical stage biopharmaceutical company focused on developing novel cancer therapies that leverage the body's immune system. Its lead candidate, IBA101, is a next-generation humanized anti-CD47 monoclonal antibody designed to target advanced solid cancers, including non-small cell lung cancer. Unlike earlier CD47 inhibitors that bind to red blood cells and cause anemia, IBA101 preferentially targets immune cells, aiming to avoid these side effects. The company is advancing IBA101 through late preclinical stages, preparing for an Investigational New Drug (IND) application, and exploring its potential synergistic effects with other immunotherapies.
Question:
What are Liminatus Pharma, Inc.'s revenue drivers?
Answer:
The company currently generates no revenue and expects future revenue to be derived from the successful development and commercialization of its product candidates, primarily IBA101.
Cut through noisy SEC filings to find the signal faster
Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.
Get Started Free →No credit card required